Can you explain the neurohormonal biventricular heart‑failure reflex?

Neurohormonal Biventricular Heart Failure Reflex

The neurohormonal biventricular heart failure reflex is a maladaptive compensatory mechanism where cardiac injury triggers sustained activation of the sympathetic nervous system (SNS) and renin-angiotensin-aldosterone system (RAAS), which initially maintains cardiovascular homeostasis but ultimately drives disease progression through hemodynamic stress and direct toxic effects on the heart and vasculature. 1

Core Pathophysiological Mechanism

The reflex cascade begins when cardiac output falls due to myocardial injury, triggering compensatory neurohormonal activation that involves multiple interconnected systems 1:

• Sympathetic nervous system activation occurs as the primary immediate response, increasing heart rate, contractility, and systemic vascular resistance to maintain perfusion 2
• RAAS activation follows, promoting sodium and water retention while increasing afterload through vasoconstriction 1
• Arginine vasopressin (AVP) system contributes to fluid retention and further vasoconstriction 2

The Cardiac Sympathetic Afferent Reflex (CSAR)

A critical component involves the cardiac sympathetic afferent reflex, which creates a vicious cycle 3:

• Metabolic and mechanical stress in the failing heart activates cardiac sympathetic afferents 3
• CSAR simultaneously increases sympathetic outflow while inhibiting the arterial baroreflex at the nucleus tractus solitarii, removing normal parasympathetic restraint 3
• This dual effect amplifies sympathoexcitation and impairs the heart's ability to respond appropriately to blood pressure changes 3

Baroreflex Dysfunction in Biventricular Failure

Arterial and cardiopulmonary baroreflex control becomes profoundly abnormal in biventricular heart failure, contributing substantially to the neurohumoral excitatory state 4:

• Baroreflex sensitivity (BRS) is markedly reduced, diminishing the heart's ability to modulate heart rate and sympathetic nerve activity in response to blood pressure fluctuations 3
• Heart rate variability (HRV) decreases, reflecting autonomic imbalance with sympathetic predominance 3
• These abnormalities persist in both systolic heart failure (HFrEF) and diastolic heart failure (HFpEF), though SNS overactivity may actually precede heart failure development due to associations with risk factors 5

Biomarker Evidence of Neurohormonal Activation

Natriuretic peptides (BNP and NT-proBNP) serve as the primary clinical biomarkers reflecting neurohormonal stress 6:

• Circulating levels rise in response to increased left ventricular end-diastolic wall stress, providing diagnostic and prognostic information 6
• In biventricular failure with right ventricular dysfunction (as seen in pulmonary hypertension or pulmonary embolism), natriuretic peptide elevations have significant prognostic value independent of left ventricular dysfunction 6
• BNP ≥100 pg/mL and NT-proBNP ≥800 pg/mL support the diagnosis of heart failure, though these thresholds require adjustment for obesity, renal dysfunction, and other comorbidities 6

Clinical Implications and Therapeutic Targets

The neurohormonal model has fundamentally transformed heart failure management 1:

• Therapeutic antagonism of neurohormonal systems forms the cornerstone of contemporary pharmacotherapy, including beta-blockers (SNS blockade), ACE inhibitors/ARBs (RAAS blockade), and mineralocorticoid receptor antagonists 1, 2
• Angiotensin receptor-neprilysin inhibitors (ARNI) like sacubitril/valsartan combine RAAS inhibition with neprilysin blocking, enhancing natriuretic peptide actions and providing superior outcomes 2
• Cardiac resynchronization therapy (CRT) acutely deactivates CSAR, increasing baroreflex sensitivity by 35% and improving heart rate variability, mechanistically explaining its sympatholytic benefits 3

Important Caveats

SNS overactivity in heart failure is modified by multiple factors beyond cardiac dysfunction alone 5:

• Coexisting noncardiac morbidities (obesity, sleep apnea, renal disease) augment sympathetic activation 5
• Immune and inflammatory factors contribute to SNS overactivity 5
• Genetic factors and demographics influence the degree of neurohormonal activation 5

The reflex operates differently across heart failure phenotypes: patients with HFpEF have lower natriuretic peptide levels than HFrEF patients for any given clinical severity due to smaller LV cavity size and lower end-diastolic wall stress, despite similarly elevated filling pressures 6.